# Acute Ischemic Stroke Interventional Study

> **NCT03803007** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acticor Biotech** · enrollment: 160 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Intravenous ACT017 1000 mg
- **OTHER:** Intravenous Placebo

## Key facts

- **NCT ID:** NCT03803007
- **Lead sponsor:** Acticor Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-06
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803007, "Acute Ischemic Stroke Interventional Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03803007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*